Uncategorized
Glaukos Corporation Announces First Quarter 2021 Financial Results
SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the first quarter ended March 31, 2021. Key highlights include: Net sales growth of 23% to $68.0 million in Q1 2021, compared to $55.3 million in Q1 2020. Glaucoma net sales of $53.7 million and Corneal Health net sales of $14.3 m